Cart
0
Get 20% Free Customization In This Report
Buy this report from - $3456

Inflammatory Bowel Disease Therapeutics Market by Drug Class (Anti-inflammatory Biologics, Non-Steroidal Anti-inflammatory drugs (NSAIDs), and Corticosteroids), by Indication (Ulcerative Colitis and Crohns disease), by Type of Molecule (Biologics and Small Molecules), by Route of Administration (Oral and Parenteral), and by Drug Form (Solid and Liquid) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_184492
Pages: NA
Jun 2018 | 188 Views
face gplus_n
Author's : NA
Tables: NA
Charts: NA
twit_n pr_n

Inflammatory bowel disease (IBD) is a broad term used to describe disorders involving chronic inflammation of digestive tract. The disease is categorized by severe diarrhea, abdominal pain, fatigue, and weight loss.

Increase in incidences of IBD and rise in adoption of anti-inflammatory drugs drive the market. In addition, strong upcoming pipeline of IBD drugs also boosts the market growth. However, side effects of these drugs over a patients body restrain the market growth. Development of biosimilars for existing drugs, and growth opportunities in the emerging economies of Asia-Pacific and LAMEA provide opportunities for the market growth.

The report segments the global inflammatory bowel disease therapeutics market based on drug class, indication, type of molecule, route of administration, drug form, and region. Based on drug class, it is divided into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. Based on indication, it is segmented into ulcerative colitis, and Crohn's disease. On the basis of type of molecule, it is bifurcated into biologics and small molecules. IBD drugs can be administered in body through oral, and parenteral routes, and are available in solid as well as liquid forms. By geography, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Key players that operate in the market include Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline plc, Merck & CO., Inc., and Novartis AG.

Key Benefits

  • The study provides an in-depth analysis of the global market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides a quantitative analysis from 2016 to 2023, which is expected to enable stakeholders to capitalize on prevailing market opportunities.
  • Competitive intelligence highlights the business practices followed by leading players across various regions.
  • Comprehensive analysis of all geographic regions is provided that helps determine prevailing opportunities in these regions.
  • Key market players are profiled and their strategies are thoroughly analyzed, which helps understand the competitive outlook of the global market.
  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework.

Inflammatory Bowel Disease Therapeutics Market Key Segments:

By Drug Class

  • Anti-inflammatory Biologics
  • Non-Steroidal Anti-inflammatory drugs (NSAIDs)
  • Corticosteroids

By Indication

  • Ulcerative Colitis
  • Crohn's disease

By Type of Molecule

  • Biologics
  • Small Molecules

By Route of Administration

  • Oral
  • Parenteral

By Drug Form

  • Solid
  • Liquid

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology

1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Analyst Tools and Models

Chapter: 2 EXECUTIVE SUMMARY

2.1 CXO Perspective

Chapter: 3 MARKET OVERVIEW

3.1 Market Definition and Scope
3.2 Top Winning Strategies
3.3 Top Player Positioning, 2016
3.4 Market Dynamics

3.4.1 Drivers
3.4.2 Restraints
3.4.3 Opportunities

Chapter: 4 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY DRUG CLASS

4.1 Overview
4.2 Market size and forecast
4.3 Anti-inflammatory Biologics

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Non-Steroidal Anti-inflammatory drugs (NSAIDs)

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Corticosteroids

4.5.1 Key market trends
4.5.2 Key growth factors and opportunities
4.5.3 Market size and forecast

Chapter: 5 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY INDICATION

5.1 Overview

5.1.1 Market size and forecast 

5.2 Ulcerative Colitis

5.2.1 Market size and forecast

5.3 Crohn's disease 

5.3.1 Market size and forecast

Chapter: 6 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY TYPE OF MOLECULE

6.1 Overview

6.1.1 Market size and forecast 

6.2 Biologics 

6.2.1 Market size and forecast

6.3 Small Molecules 

6.3.1 Market size and forecast

Chapter: 7 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

7.1 Overview

7.1.1 Market size and forecast 

7.2 Oral 

7.2.1 Market size and forecast

7.3 Parenteral  

7.3.1 Market size and forecast

Chapter: 8 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY DRUG FORM

8.1 Overview

8.1.1 Market size and forecast 

8.2 Solid 

8.2.1 Market size and forecast

8.3 Liquid 

8.3.1 Market size and forecast

Chapter: 9 GLOBAL INFLAMMATORY BOWEL DISEASE THERAPEUTICS MARKET, BY REGION

9.1 Overview

9.1.1 Market size and forecast 

9.2 North America

9.2.1 Key market trends
9.2.2 Key growth factors and opportunities
9.2.3 Market size and forecast

9.2.3.1 U.S.

9.2.3.1.1 U.S. inflammatory bowel disease therapeutics market by drug class
9.2.3.1.2 U.S. inflammatory bowel disease therapeutics market by indication
9.2.3.1.3 U.S. inflammatory bowel disease therapeutics market by type of molecule
9.2.3.1.4 U.S. inflammatory bowel disease therapeutics market by route of administration
9.2.3.1.5 U.S. inflammatory bowel disease therapeutics market by drug form

9.2.3.2 Canada

9.2.3.2.1 Canada inflammatory bowel disease therapeutics market by drug class
9.2.3.2.2 Canada inflammatory bowel disease therapeutics market by indication
9.2.3.2.3 Canada inflammatory bowel disease therapeutics market by type of molecule
9.2.3.2.4 Canada inflammatory bowel disease therapeutics market by route of administration
9.2.3.2.5 Canada inflammatory bowel disease therapeutics market by drug form

9.2.3.3 Mexico

9.2.3.3.1 Mexico inflammatory bowel disease therapeutics market by drug class
9.2.3.3.2 Mexico inflammatory bowel disease therapeutics market by indication
9.2.3.3.3 Mexico inflammatory bowel disease therapeutics market by type of molecule
9.2.3.3.4 Mexico inflammatory bowel disease therapeutics market by route of administration
9.2.3.3.5 Mexico inflammatory bowel disease therapeutics market by drug form

9.2.4 North America inflammatory bowel disease therapeutics market by drug class
9.2.5 North America inflammatory bowel disease therapeutics market by indication
9.2.6 North America inflammatory bowel disease therapeutics market by type of molecule
9.2.7 North America inflammatory bowel disease therapeutics market by route of administration
9.2.8 North America inflammatory bowel disease therapeutics market by drug form

9.3 Europe 

9.3.1 Key market trends
9.3.2 Key growth factors and opportunities
9.3.3 Market size and forecast

9.3.3.1 Germany

9.3.3.1.1 Germany inflammatory bowel disease therapeutics market by drug class
9.3.3.1.2 Germany inflammatory bowel disease therapeutics market by indication
9.3.3.1.3 Germany inflammatory bowel disease therapeutics market by type of molecule
9.3.3.1.4 Germany inflammatory bowel disease therapeutics market by route of administration
9.3.3.1.5 Germany inflammatory bowel disease therapeutics market by drug form

9.3.3.2 France

9.3.3.2.1 France inflammatory bowel disease therapeutics market by drug class
9.3.3.2.2 France inflammatory bowel disease therapeutics market by indication
9.3.3.2.3 France inflammatory bowel disease therapeutics market by type of molecule
9.3.3.2.4 France inflammatory bowel disease therapeutics market by route of administration
9.3.3.2.5 France inflammatory bowel disease therapeutics market by drug form

9.3.3.3 UK

9.3.3.3.1 UK inflammatory bowel disease therapeutics market by drug class
9.3.3.3.2 UK inflammatory bowel disease therapeutics market by indication
9.3.3.3.3 UK inflammatory bowel disease therapeutics market by type of molecule
9.3.3.3.4 UK inflammatory bowel disease therapeutics market by route of administration
9.3.3.3.5 UK inflammatory bowel disease therapeutics market by drug form

9.3.3.4 Italy

9.3.3.4.1 Italy inflammatory bowel disease therapeutics market by drug class
9.3.3.4.2 Italy inflammatory bowel disease therapeutics market by indication
9.3.3.4.3 Italy inflammatory bowel disease therapeutics market by type of molecule
9.3.3.4.4 Italy inflammatory bowel disease therapeutics market by route of administration
9.3.3.4.5 Italy inflammatory bowel disease therapeutics market by drug form

9.3.3.5 Spain

9.3.3.5.1 Spain inflammatory bowel disease therapeutics market by drug class
9.3.3.5.2 Spain inflammatory bowel disease therapeutics market by indication
9.3.3.5.3 Spain inflammatory bowel disease therapeutics market by type of molecule
9.3.3.5.4 Spain inflammatory bowel disease therapeutics market by route of administration
9.3.3.5.5 Spain inflammatory bowel disease therapeutics market by drug form

9.3.3.6 Rest of Europe

9.3.3.6.1 Rest of Europe inflammatory bowel disease therapeutics market by drug class
9.3.3.6.2 Rest of Europe inflammatory bowel disease therapeutics market by indication
9.3.3.6.3 Rest of Europe inflammatory bowel disease therapeutics market by type of molecule
9.3.3.6.4 Rest of Europe inflammatory bowel disease therapeutics market by route of administration
9.3.3.6.5 Rest of Europe inflammatory bowel disease therapeutics market by drug form

9.3.4 Europe inflammatory bowel disease therapeutics market by drug class
9.3.5 Europe inflammatory bowel disease therapeutics market by indication
9.3.6 Europe inflammatory bowel disease therapeutics market by type of molecule
9.3.7 Europe inflammatory bowel disease therapeutics market by route of administration
9.3.8 Europe inflammatory bowel disease therapeutics market by drug form

9.4 Asia-Pacific

9.4.1 Key market trends
9.4.2 Key growth factors and opportunities
9.4.3 Market size and forecast

9.4.3.1 Japan

9.4.3.1.1 Japan inflammatory bowel disease therapeutics market by drug class
9.4.3.1.2 Japan inflammatory bowel disease therapeutics market by indication
9.4.3.1.3 Japan inflammatory bowel disease therapeutics market by type of molecule
9.4.3.1.4 Japan inflammatory bowel disease therapeutics market by route of administration
9.4.3.1.5 Japan inflammatory bowel disease therapeutics market by drug form

9.4.3.2 China

9.4.3.2.1 China inflammatory bowel disease therapeutics market by drug class
9.4.3.2.2 China inflammatory bowel disease therapeutics market by indication
9.4.3.2.3 China inflammatory bowel disease therapeutics market by type of molecule
9.4.3.2.4 China inflammatory bowel disease therapeutics market by route of administration
9.4.3.2.5 China inflammatory bowel disease therapeutics market by drug form

9.4.3.3 India

9.4.3.3.1 India inflammatory bowel disease therapeutics market by drug class
9.4.3.3.2 India inflammatory bowel disease therapeutics market by indication
9.4.3.3.3 India inflammatory bowel disease therapeutics market by type of molecule
9.4.3.3.4 India inflammatory bowel disease therapeutics market by route of administration
9.4.3.3.5 India inflammatory bowel disease therapeutics market by drug form

9.4.3.4 Australia

9.4.3.4.1 Australia inflammatory bowel disease therapeutics market by drug class
9.4.3.4.2 Australia inflammatory bowel disease therapeutics market by indication
9.4.3.4.3 Australia inflammatory bowel disease therapeutics market by type of molecule
9.4.3.4.4 Australia inflammatory bowel disease therapeutics market by route of administration
9.4.3.4.5 Australia inflammatory bowel disease therapeutics market by drug form

9.4.3.5 South Korea

9.4.3.5.1 South Korea inflammatory bowel disease therapeutics market by drug class
9.4.3.5.2 South Korea inflammatory bowel disease therapeutics market by indication
9.4.3.5.3 South Korea inflammatory bowel disease therapeutics market by type of molecule
9.4.3.5.4 South Korea inflammatory bowel disease therapeutics market by route of administration
9.4.3.5.5 South Korea inflammatory bowel disease therapeutics market by drug form

9.4.3.6 Rest of Asia-Pacific

9.4.3.6.1 Rest of Asia-Pacific inflammatory bowel disease therapeutics market by drug class
9.4.3.6.2 Rest of Asia-Pacific inflammatory bowel disease therapeutics market by indication
9.4.3.6.3 Rest of Asia-Pacific inflammatory bowel disease therapeutics market by type of molecule
9.4.3.6.4 Rest of Asia-Pacific inflammatory bowel disease therapeutics market by route of administration
9.4.3.6.5 Rest of Asia-Pacific inflammatory bowel disease therapeutics market by drug form

9.4.4 Asia-Pacific inflammatory bowel disease therapeutics market by drug class
9.4.5 Asia-Pacific inflammatory bowel disease therapeutics market by indication
9.4.6 Asia-Pacific inflammatory bowel disease therapeutics market by type of molecule
9.4.7 Asia-Pacific inflammatory bowel disease therapeutics market by route of administration
9.4.8 Asia-Pacific inflammatory bowel disease therapeutics market by drug form

9.5 LAMEA

9.5.1 Key market trends
9.5.2 Key growth factors and opportunities
9.5.3 Market size and forecast

9.5.3.1 Brazil

9.5.3.1.1 Brazil inflammatory bowel disease therapeutics market by drug class
9.5.3.1.2 Brazil inflammatory bowel disease therapeutics market by indication
9.5.3.1.3 Brazil inflammatory bowel disease therapeutics market by type of molecule
9.5.3.1.4 Brazil inflammatory bowel disease therapeutics market by route of administration
9.5.3.1.5 Brazil inflammatory bowel disease therapeutics market by drug form

9.5.3.2 Saudi Arabia market size and forecast

9.5.3.2.1 Saudi Arabia inflammatory bowel disease therapeutics market by drug class
9.5.3.2.2 Saudi Arabia inflammatory bowel disease therapeutics market by indication
9.5.3.2.3 Saudi Arabia inflammatory bowel disease therapeutics market by type of molecule
9.5.3.2.4 Saudi Arabia inflammatory bowel disease therapeutics market by route of administration
9.5.3.2.5 Saudi Arabia inflammatory bowel disease therapeutics market by drug form

9.5.3.3 South Africa market size and forecast

9.5.3.3.1 South Africa inflammatory bowel disease therapeutics market by drug class
9.5.3.3.2 South Africa inflammatory bowel disease therapeutics market by indication
9.5.3.3.3 South Africa inflammatory bowel disease therapeutics market by type of molecule
9.5.3.3.4 South Africa inflammatory bowel disease therapeutics market by route of administration
9.5.3.3.5 South Africa inflammatory bowel disease therapeutics market by drug form

9.5.3.4 Rest of LAMEA

9.5.3.4.1 Rest of LAMEA inflammatory bowel disease therapeutics market by drug class
9.5.3.4.2 Rest of LAMEA inflammatory bowel disease therapeutics market by indication
9.5.3.4.3 Rest of LAMEA inflammatory bowel disease therapeutics market by type of molecule
9.5.3.4.4 Rest of LAMEA inflammatory bowel disease therapeutics market by route of administration
9.5.3.4.5 Rest of LAMEA inflammatory bowel disease therapeutics market by drug form

9.5.4 LAMEA inflammatory bowel disease therapeutics market by drug class
9.5.5 LAMEA inflammatory bowel disease therapeutics market by indication
9.5.6 LAMEA inflammatory bowel disease therapeutics market by type of molecule
9.5.7 LAMEA inflammatory bowel disease therapeutics market by route of administration
9.5.8 LAMEA inflammatory bowel disease therapeutics market by drug form

Chapter: 10 COMPANY PROFILES

10.1 Abbvie, Inc.

10.1.1 Overview 
10.1.2 Company snapshot 
10.1.3 Business performance 
10.1.4 Operating segment overview
10.1.5 Strategic moves and developments 

10.2 Johnson & Johnson

10.2.1 Overview 
10.2.2 Company snapshot 
10.2.3 Business performance 
10.2.4 Operating segment overview
10.2.5 Strategic moves and developments 

10.3 GlaxoSmithKline plc

10.3.1 Overview 
10.3.2 Company snapshot 
10.3.3 Business performance 
10.3.4 Operating segment overview
10.3.5 Strategic moves and developments 

10.4 Merck & CO., Inc.

10.4.1 Overview 
10.4.2 Company snapshot 
10.4.3 Business performance 
10.4.4 Operating segment overview
10.4.5 Strategic moves and developments

10.5 Novartis AG

10.5.1 Overview 
10.5.2 Company snapshot 
10.5.3 Business performance 
10.5.4 Operating segment overview
10.5.5 Strategic moves and developments 

 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Inflammatory Bowel Disease Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts